ReviewCancers2026
A Current Overview of Quality-of-Life Research in Chronic Myeloid Leukemia (CML).
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThe introduction of tyrosine kinase inhibitors has transformed chronic myeloid leukemia into a chronic condition with near-normal life expectancy, shifting clinical priorities toward long-term tolerability, symptom burden, and health-related quality of life. This review aims to synthesize current evidence on patient-reported outcomes and quality of life in chronic myeloid leukemia, with particular focus on fatigue, differences across therapies, associations with molecular response and treatment-free remission, and health utility outcomes.
methodsA narrative review of published clinical trials, observational studies, and patient-reported outcome research in chronic myeloid leukemia during the tyrosine kinase inhibitor era was conducted. Evidence from generic, cancer-specific, and disease-specific quality-of-life instruments was examined, together with studies evaluating dose reduction, treatment discontinuation, and survivorship outcomes.
resultsAcross studies, patients with chronic myeloid leukemia experience persistent impairments in quality of life compared with the general population despite effective disease control. Fatigue consistently emerges as the dominant symptom associated with functional limitation and reduced well-being. Comparative analyses across tyrosine kinase inhibitors demonstrate generally modest and inconsistent differences in global quality of life. Deeper molecular responses, dose reduction, and treatment-free remission are commonly associated with stabilization or improvement in patient-reported outcomes, although symptoms may persist in a subset of patients. Methodological limitations include heterogeneity of instruments, predominance of cross-sectional designs, and lack of established minimal important differences for disease-specific measures.
conclusionsIn the modern treatment era, chronic myeloid leukemia is characterized by excellent survival but an ongoing quality-of-life burden, largely driven by fatigue. Future research should prioritize longitudinal patient-reported outcome collection, methodological standardization, and development of clinically meaningful thresholds to better align disease control with patient-centered outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.